Monoclonal antibody treatments typically cost between $15,000 and $200,000 per year in the United States, with some cancer regimens exceeding $500,000 annually. The price depends heavily on the condition being treated, how often infusions are needed, and whether a biosimilar alternative exists. On top of the drug itself, you’ll pay facility and administration fees for each infusion session.
Costs by Condition
The price range for monoclonal antibodies is enormous because these drugs treat everything from psoriasis to advanced cancer. Here’s what the major categories look like.
For autoimmune conditions like rheumatoid arthritis, Crohn’s disease, and psoriasis, annual list prices run in the mid-five to low-six figures. In 2022, a year’s supply of Humira (adalimumab) cost about $90,564, while Stelara (ustekinumab) ran roughly $149,952. These are among the most commonly prescribed monoclonal antibodies, and many patients take them for years or even decades.
Cancer immunotherapy sits higher on the price scale. A single dose of Keytruda (pembrolizumab), given every three weeks, carries a list price of roughly $5,500 based on Merck’s pricing transparency data. Over a full year, that adds up quickly. The average yearly cost of cancer monoclonal antibodies was about $96,731 as of 2018, though prices have continued climbing. For blood cancers like multiple myeloma, combination regimens that include a monoclonal antibody alongside other drugs can reach $300,000 to $600,000 per year. One common first-line multiple myeloma regimen combining daratumumab, lenalidomide, and a steroid totals roughly $405,000 annually.
Newer Alzheimer’s disease antibodies fall in a more moderate range. Leqembi (lecanemab) has an annual wholesale cost of $26,500, while Kisunla (donanemab) is priced at $32,000 per year. Kisunla may actually cost less in practice for some patients because treatment can be stopped once brain scans show sufficient clearance of amyloid plaques, with potential costs ranging from about $12,500 for six months to $48,700 for 18 months.
Why These Drugs Cost So Much
Monoclonal antibodies aren’t made like typical pills. They’re biological molecules produced by living cells, most commonly Chinese hamster ovary (CHO) cells grown in massive bioreactors. This manufacturing process is capital-intensive, requires expensive raw materials, and takes far longer to develop than conventional chemical drug production. The purity standards are also stricter than for most other biological products: monoclonal antibodies generally need to meet 98% purity or higher, and every impurity above 1% must be fully characterized.
These biological constraints translate directly into price. Facilities cost hundreds of millions of dollars to build, each production batch takes weeks, and quality testing is extensive. Other proteins like industrial enzymes or blood products can be manufactured far more cheaply using simpler technologies, but the regulatory framework for therapeutic antibodies demands a level of precision that keeps costs high.
Infusion and Administration Fees
The sticker price of the drug isn’t the full bill. Most monoclonal antibodies are given by IV infusion in a clinic or hospital outpatient setting, and each session carries its own administration charge. These fees average roughly $300 to $500 per visit, though the range varies by insurance type and the complexity of the infusion. Patients with managed care insurance pay the most in administration costs (averaging around $504 per visit), while Medicaid patients pay the least (about $92). If you’re receiving multiple drugs during a single visit, administration costs climb further, reaching $693 or more for three-drug combinations.
About three-quarters of the administration fee covers the actual infusion time, with the remainder going to monitoring, diagnostics, and hydration. Over the course of a year with biweekly or monthly infusions, these fees add thousands of dollars beyond the drug cost alone.
What You’ll Actually Pay Out of Pocket
Your out-of-pocket cost depends almost entirely on your insurance situation. For monoclonal antibodies given by infusion in a medical setting, Medicare covers them under Part B. After meeting the annual Part B deductible, you’re responsible for 20% of the Medicare-approved amount. On a $26,500 Alzheimer’s drug, that 20% coinsurance alone is over $5,000 per year, and on a $165,000 cancer antibody, it’s $33,000.
Private insurance typically covers monoclonal antibodies but places many of them on specialty tiers with higher copays or coinsurance. Your plan’s formulary determines which drugs are covered and at what cost-sharing level. Some self-injectable antibodies (like Humira) may fall under your pharmacy benefit rather than your medical benefit, which can change the math significantly depending on your plan’s structure.
Biosimilars Can Cut Costs Significantly
Biosimilars are near-identical copies of brand-name monoclonal antibodies, approved by the FDA after the original drug’s patent exclusivity expires. They typically cost about 30% less than the original, though discounts range from 10% to 51% depending on the drug and market competition. For a drug like Humira, which now has multiple biosimilar competitors, that 30% discount translates to savings of roughly $27,000 per year at list price.
The biosimilar market is still maturing. Uptake has been slower than many predicted, partly because rebate arrangements between manufacturers and insurers sometimes make brand-name drugs cheaper for insurers even when biosimilars have lower list prices. Still, biosimilar competition is the single biggest factor likely to reduce what patients pay for established monoclonal antibody therapies.
Financial Assistance Options
Most manufacturers of high-cost monoclonal antibodies offer copay assistance programs that can dramatically reduce out-of-pocket costs, sometimes to $0 or close to it. These programs are available to patients with commercial or private insurance and generally have no income limits. The catch: if you have Medicare, Medicaid, or Medicare Advantage (even through a commercial carrier), you don’t qualify for manufacturer copay programs. You also can’t qualify if you have commercial insurance as your primary coverage but carry any government insurance as a secondary plan.
For patients on government insurance or without adequate coverage, independent grant programs exist for specific diseases. These programs do have income requirements, typically tied to the federal poverty level, and your prescribed medication must be listed under the relevant disease fund. Your medication also needs to be covered by your existing insurance plan. These grants help underinsured patients with life-threatening, chronic, and rare diseases access treatment they otherwise couldn’t afford.
Hospital systems like Mayo Clinic maintain dedicated staff to help patients navigate these programs. If you’re facing a monoclonal antibody prescription, asking your provider’s billing or financial services department about assistance options before your first infusion can save you thousands of dollars over the course of treatment.